Literature DB >> 28739267

H. pylori seroprevalence and risk of diabetes: An ancillary case-control study nested in the diabetes prevention program.

Saud Alzahrani1, Jason Nelson2, Steven F Moss3, Jessica K Paulus2, William C Knowler4, Anastassios G Pittas5.   

Abstract

OBJECTIVE: To determine the association between H. pylori infection and risk of incident diabetes in adults at high risk for diabetes who participated in the Diabetes Prevention Program (DPP) study.
METHODS: In a nested case-control study conducted among 421 adults with newly diagnosed diabetes and 421 matched controls, we examined the association between serological status of H. pylori at baseline and risk of incident diabetes over a mean follow-up period of 2.6years. Using data from the baseline visit of the DPP, we also examined the cross-sectional association between presence of H. pylori antibodies and insulin sensitivity, insulin secretion and the disposition index-like measure after a 75-g oral glucose tolerance test (OGTT).
RESULTS: At baseline, H. pylori antibodies were present in 40% of participants who developed diabetes and 39% of controls. After adjusting for matching factors, there was no association between exposure to H. pylori and incident diabetes (odds ratio [OR] of 1.04 (95% CI, 0.77 to 1.40). In cross-sectional analyses, H. pylori status was not significantly associated with insulin sensitivity and disposition index-like measure from OGTT.
CONCLUSIONS: In adults at high risk for diabetes, H. pylori seropositivity was not associated with risk of developing diabetes.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Case–control; Diabetes mellitus; Diabetes prevention program; H. pylori; Metabolic syndrome; Observational study

Mesh:

Substances:

Year:  2017        PMID: 28739267      PMCID: PMC5603174          DOI: 10.1016/j.jdiacomp.2017.05.015

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  39 in total

1.  Low plasma ghrelin levels in patients with Helicobacter pylori-associated gastritis.

Authors:  Hajime Isomoto; Masamitsu Nakazato; Hiroaki Ueno; Yukari Date; Yoshito Nishi; Hiroshi Mukae; Yohei Mizuta; Akira Ohtsuru; Shunichi Yamashita; Shigeru Kohno
Journal:  Am J Med       Date:  2004-09-15       Impact factor: 4.965

2.  Eradication of insulin resistance.

Authors:  Junta Imai; Tetsuya Yamada; Tokuo Saito; Yasushi Ishigaki; Yoshinori Hinokio; Hidetoshi Kotake; Yoshitomo Oka; Hideki Katagiri
Journal:  Lancet       Date:  2009-07-18       Impact factor: 79.321

3.  Increased prevalence of Helicobacter pylori in patients with diabetes mellitus.

Authors:  M Marrollo; G Latella; D Melideo; E Storelli; R Iannarelli; P Stornelli; M Valenti; R Caprilli
Journal:  Dig Liver Dis       Date:  2001 Jan-Feb       Impact factor: 4.088

4.  Helicobacter pylori infection and insulin-dependent diabetes mellitus.

Authors:  D A de Luis; H de la Calle; G Roy; C M de Argila; S Valdezate; R Canton; D Boixeda
Journal:  Diabetes Res Clin Pract       Date:  1998-02       Impact factor: 5.602

5.  Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.

Authors:  Abbas E Kitabchi; Marinella Temprosa; William C Knowler; Steven E Kahn; Sarah E Fowler; Steven M Haffner; Reuben Andres; Christopher Saudek; Sharon L Edelstein; Richard Arakaki; Mary Beth Murphy; Harry Shamoon
Journal:  Diabetes       Date:  2005-08       Impact factor: 9.461

6.  The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.

Authors: 
Journal:  Diabetes Care       Date:  1999-04       Impact factor: 19.112

7.  Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ethnic disparities.

Authors:  Yonatan H Grad; Marc Lipsitch; Allison E Aiello
Journal:  Am J Epidemiol       Date:  2011-11-15       Impact factor: 4.897

8.  Insulin resistance in H pylori infection and its association with oxidative stress.

Authors:  Mehmet Aslan; Mehmet Horoz; Yasar Nazligul; Cengiz Bolukbas; F Fusun Bolukbas; Sahbettin Selek; Hakim Celik; Ozcan Erel
Journal:  World J Gastroenterol       Date:  2006-11-14       Impact factor: 5.742

Review 9.  CagA-mediated pathogenesis of Helicobacter pylori.

Authors:  Abolghasem Tohidpour
Journal:  Microb Pathog       Date:  2016-01-12       Impact factor: 3.738

10.  Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels.

Authors:  Kristina M Utzschneider; Ronald L Prigeon; Mirjam V Faulenbach; Jenny Tong; Darcy B Carr; Edward J Boyko; Donna L Leonetti; Marguerite J McNeely; Wilfred Y Fujimoto; Steven E Kahn
Journal:  Diabetes Care       Date:  2008-10-28       Impact factor: 19.112

View more
  4 in total

1.  Diagnostic gene biomarkers for predicting immune infiltration in endometriosis.

Authors:  Chengmao Xie; Chang Lu; Yong Liu; Zhaohui Liu
Journal:  BMC Womens Health       Date:  2022-05-18       Impact factor: 2.742

2.  Association of Helicobacter pylori infection with the risk of metabolic syndrome and insulin resistance: an updated systematic review and meta-analysis.

Authors:  Mobin Azami; Hamid Reza Baradaran; Hojat Dehghanbanadaki; Parisa Kohnepoushi; Lotfolah Saed; Asra Moradkhani; Farhad Moradpour; Yousef Moradi
Journal:  Diabetol Metab Syndr       Date:  2021-12-18       Impact factor: 3.320

Review 3.  Helicobacter pylori infection and liver diseases: Epidemiology and insights into pathogenesis.

Authors:  Kazuya Okushin; Takeya Tsutsumi; Kazuhiko Ikeuchi; Akira Kado; Kenichiro Enooku; Hidetaka Fujinaga; Kyoji Moriya; Hiroshi Yotsuyanagi; Kazuhiko Koike
Journal:  World J Gastroenterol       Date:  2018-08-28       Impact factor: 5.742

4.  Helicobacter pylori infection as a risk factor for diabetes: a meta-analysis of case-control studies.

Authors:  Kamyar Mansori; Yousef Moradi; Sara Naderpour; Roya Rashti; Ali Baradaran Moghaddam; Lotfolah Saed; Hedyeh Mohammadi
Journal:  BMC Gastroenterol       Date:  2020-03-24       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.